More Melanoma, Less Prostate Cancer; Aggressive End-of-Life Care; J&J Has Friends

New projections for cancer trends over the next 2 decades suggest that the incidence of melanoma will continue to increase, and that there will be more deaths from pancreatic and liver cancers, fewer cases of prostate cancer, and fewer breast cancer deaths. (JAMA Network Open)

Aggressive end-of-life care remains the norm for many women with terminal ovarian cancer, despite guidelines that encourage earlier use of palliative care. (Michigan Medicine, Cancer)

Diet and exercise may improve the anticancer activity of chemotherapy for pediatric leukemia. (American Society of Hematology)

Despite its recent FDA approval, the CAR T-cell therapy idecabtagene vicleucel (Abecma) is not a cost-effective therapy for multiple myeloma, according to an analysis by the Institute for Clinical and Economic Review. (Biopharma Dive)

Less-invasive surgery for uterine leiomyomas led to a higher rate of additional surgical procedures within 1 year as compared with hysterectomy. (Obstetrics & Gynecology)

Gilead Sciences announced full FDA approval of sacituzumab govitecan-hziy (Trodelvy) for metastatic triple-negative breast cancer, following positive results from the phase III ASCENT study.

Adjuvant pembrolizumab (Keytruda) significantly improved disease-free survival versus placebo following surgery for kidney cancer, Merck announced.

Nivolumab (Opdivo) plus either chemotherapy or ipilimumab (Yervoy) significantly improved overall survival versus chemotherapy alone for unresectable or metastatic esophageal cancer, according to Bristol Myers Squibb.

Stressed-out cells form a common molecular thread woven into cancer, Parkinson’s disease, and type 2 diabetes. (Salk Institute)

CAR T-cell therapy followed by stem-cell transplantation may offer the best strategy for relapse-free survival in pediatric acute lymphoblastic leukemia. (UVA Health)

The U.S. Chamber of Commerce and multiple other business organizations have filed amicus briefs in support of Johnson & Johnson’s Supreme Court appeal to overturn a $2.1 billion verdict for claims that the company’s talc-based products cause cancer. (Fierce Pharma)